Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Indacaterol leads to higher number of participants with clinically significant improvement in… compared with placebo (high certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Indacaterol leads to lower number of participants experiencing 1 or more exacerbations compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in number of participants with a clinically significant improvement in… compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ School‐age children · School‐aged children and adults
Intermittent ICS showed no clear difference in exacerbations requiring oral corticosteroids ‐ School‐age children compared with placebo (low certainty).
1 finding from 1 review
QoL · Preschool children (<6 years)
1 finding from 1 review
Day time asthma score Standardised mean difference · Preschool children (<6 years)
1 finding from 1 review
Night time asthma score Mean difference · Preschool children (<6 years)
1 finding from 1 review
Adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · School‐aged children and adults
Intermittent ICS showed no clear difference in exacerbations requiring oral corticosteroids ‐ adults compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · School‐aged children and adults
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Day time asthma score Mean difference · School‐aged children and adults
1 finding from 1 review
Night time asthma score Mean difference · School‐aged children and adults
1 finding from 1 review
Adverse events · School‐aged children and adults
Intermittent ICS showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · Preschool children (<6 years)
Intermittent ICS probably leads to lower exacerbations requiring oral corticosteroids compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Hospital admissions · Preschool children (<6 years)
It is very uncertain whether intermittent ICS changes hospitalisations compared with placebo (very low certainty).
1 finding from 1 review